
RoyalCare Super Speciality Hospital Unlisted Share Price
RoyalCare Super Speciality Hospital Limited
- CIN
- U85100TZ2012PLC018984
- ISIN
- INE02C801010
- Incorporated
- 4 Dec 2012
- Registered state
- Tamil Nadu
Key valuation
- Market cap
- ₹2,868 Cr
- P/E
- 191.2x
- Debt / equity
- 1.3x
- Shares outstanding
- 18,86,84,211
Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.
Price history
Dated dealer-quote averages, plotted on a true time scale. There is no continuous trading behind these numbers.
About RoyalCare Super Speciality Hospital
RoyalCare Super Speciality Hospital Limited runs Royal Care Hospital in Coimbatore, Tamil Nadu. The hospital opened in 2015 with 50 beds and has grown to about 750 beds, with its main campus at Neelambur.
It offers cardiology, neurology, oncology, nephrology, organ transplants and emergency care, and was an early adopter in the region of treatments such as bronchial thermoplasty for severe asthma. The hospital is JCI accredited. Dr. K. Madeswaran is the Chairman and Managing Director.
RoyalCare reported revenue of ₹353 crore and a net profit of ₹15 crore in FY2025, compared with ₹333 crore and ₹25 crore in FY2024.
Key highlights
- Incorporated in 2015
Financial snapshot
FY2025
- Revenue FY2025
- ₹352.60 Cr
- EBITDA
- ₹60.40 Cr
- PAT
- ₹15.00 Cr
- Net worth
- ₹317.80 Cr
- Total debt
- ₹425.20 Cr
- Cash & equivalents
- —
- Operating cash flow
- ₹132.50 Cr
- EPS
- ₹0.79
Management & board
- KMSince 2017
Koduvai Muthusamy Gounder Subramanian
Director
- MPSince 2017
Maistrykadu Palaniswamy Prabhu
Director
- KKSince 2017
Kaluveripalayam Kumarasamy Chandrasekar
Director
- C.Since 2012
Chockalingam .
Director
- KGSince 2015
Karuppa Gounder Rangasamy
Company Secretary
- KMSince 2012
Karuppanasamy Madeswaran
Managing Director
- KPSince 2012
Kalingarayanpalayam Ponnusamy Alagesan
Director
- KKSince 2017
Kalyana Kumari Sankara Krishnan
Director
- S.Since 2017
Shanmugapriya .
Director
- SPSince 2017
Subramanian Paulvannan
Director
- SMSince 2017
Sudhakaran Manickam
Director
- PVSince 2017
Pattabhiraman Vallandraman Ranganathan
Director
- PGSince 2017
Perumal Gounder Chokkalingam
Director
- NSSince 2017
Natarajan Sudhakar
Director
- KMSince 2018
Karuppusamy Muthusamy Muthusamy
Director
- TBSince 2021
Thangavelu Balachander
CFO, Director
- MMSince 2024
Madeswaran Minu
Director
- APSince 2025
Appukutty Palanisamy
Director
Reported financials · FY2022–FY2025
Figures in ₹ crore unless stated.
| Particulars | FY2022 | FY2023 | FY2024 | FY2025 | YoY | CAGR |
|---|---|---|---|---|---|---|
| Profit & loss | ||||||
| Revenue from operationsYoY +6.0%CAGR +5.4% | 301 | 306 | 333 | 353 | +6.0% | +5.4% |
| Other incomeYoY +63.5%CAGR +26.5% | 4 | 5 | 5 | 9 | +63.5% | +26.5% |
| Total expensesYoY +10.1%CAGR +6.7% | 284 | 295 | 314 | 345 | +10.1% | +6.7% |
| EBITDAYoY -14.9%CAGR -5.8% | 72 | 67 | 71 | 60 | -14.9% | -5.8% |
| Depreciation & amortisationYoY +2.0%CAGR +1.8% | 24 | 24 | 25 | 25 | +2.0% | +1.8% |
| EBITYoY -23.9%CAGR -10.0% | 49 | 42 | 47 | 35 | -23.9% | -10.0% |
| Finance costYoY -11.3%CAGR -10.2% | 27 | 27 | 22 | 20 | -11.3% | -10.2% |
| Profit before taxYoY -35.4%CAGR -9.7% | 21 | 16 | 24 | 16 | -35.4% | -9.7% |
| Tax expenseYoY —CAGR +81.7% | 0 | -0 | -0 | 1 | — | +81.7% |
| Profit after taxYoY -38.8%CAGR -10.9% | 21 | 16 | 25 | 15 | -38.8% | -10.9% |
| Earnings per shareYoY -39.2%CAGR -11.0% | ₹1.12 | ₹0.83 | ₹1.30 | ₹0.79 | -39.2% | -11.0% |
| Balance sheet | ||||||
| Net worthYoY +63.2%CAGR +39.1% | 118 | 134 | 195 | 318 | +63.2% | +39.1% |
| Total debtYoY +45.9%CAGR +18.4% | 256 | 244 | 291 | 425 | +45.9% | +18.4% |
| Current liabilitiesYoY +13.9%CAGR +12.7% | 115 | 130 | 145 | 165 | +13.9% | +12.7% |
| Current assetsYoY +13.5%CAGR +13.2% | 145 | 165 | 185 | 211 | +13.5% | +13.2% |
| Total assetsYoY +48.8%CAGR +26.0% | 406 | 421 | 545 | 811 | +48.8% | +26.0% |
| Cash flow | ||||||
| Operating activitiesYoY +14.8%CAGR +15.8% | 85 | 99 | 115 | 133 | +14.8% | +15.8% |
| Investing activities | -62 | -75 | -85 | -99 | — | — |
| Financing activities | -22 | -25 | -28 | -32 | — | — |
| Free cash flowYoY +15.8%CAGR +15.2% | 62 | 72 | 82 | 95 | +15.8% | +15.2% |
| Net change in cashYoY -11.1%CAGR +2.2% | 2 | -1 | 2 | 2 | -11.1% | +2.2% |
YoY compares the latest year with the one before it. CAGR runs from the oldest reported year to the latest. A dash means the year is missing, or the starting figure is zero or negative, so a percentage would mislead.
Margins, returns, liquidity, leverage and every other ratio from these figures: see RatiosRevenue, EBITDA and PAT
₹ crore. A year with no reported figure is left out rather than drawn as zero.
- Revenue
- EBITDA
- PAT
Every ratio here is worked out from the reported figures in the Financials tab, and valuation multiples from the indicative price in the header. Nothing is a stored value. A ratio the filings cannot support (a line not reported, or a zero or negative base) is left out or shown as —, never as a misleading number. Balance-sheet ratios use year-end figures.
Valuation multiples
What the indicative price pays for the latest year's earnings, book and cash. On FY2025 figures and the ₹152 indicative price.
- Market cap
- ₹2,868 Cr
- Enterprise value
- ₹3,293 Cr
- Price / earnings (P/E)
- 191.20x
- Price / book (P/B)
- 9.02x
- Price / sales (P/S)
- 8.13x
- Price / operating cash flow
- 21.65x
- EV / EBITDA
- 54.52x
- EV / EBIT
- 93.03x
- EV / sales
- 9.34x
- Earnings yield
- 0.5%
- Free cash flow yield
- 3.3%
How these are worked out
- Market cap
- Indicative price × shares outstanding
- Enterprise value
- Market cap + debt − cash
- Price / earnings (P/E)
- Market cap ÷ PAT (profitable years only)
- Price / book (P/B)
- Market cap ÷ net worth
- Price / sales (P/S)
- Market cap ÷ revenue from operations
- Price / operating cash flow
- Market cap ÷ cash from operating activities
- EV / EBITDA
- Enterprise value ÷ EBITDA
- EV / EBIT
- Enterprise value ÷ (EBITDA − depreciation)
- EV / sales
- Enterprise value ÷ revenue from operations
- Earnings yield
- PAT ÷ market cap
- Free cash flow yield
- (Operating cash flow − capex) ÷ market cap
IPO / listing status
The company has not announced IPO details such as a DRHP filing, an expected window or its bankers. This section will update once it does.
Research & news
Information currently unavailable
Nothing has been published on RoyalCare Super Speciality Hospital yet. Research, news and articles tagged with it will appear here when they are.
Documents
Private documents are shown locked and are released to verified clients on request.
RoyalCare Super Speciality Hospital unlisted shares: FAQs
What is the RoyalCare Super Speciality Hospital unlisted share price today?
The indicative price of RoyalCare Super Speciality Hospital Limited shares is ₹152 per share, as of 17 Nov 2026. Unlisted shares have no exchange price: this figure reflects recent off-market deals and can differ from the price on a particular trade. The price history on this page shows how it has moved.
How can I buy RoyalCare Super Speciality Hospital unlisted shares?
Raise a buy enquiry on this page with the number of shares you want. Our desk confirms availability and the price, you pay from a bank account in your own name, and the shares are transferred to your demat account. You need a PAN and a demat account with any depository participant.
How can I sell RoyalCare Super Speciality Hospital shares?
Raise a sell enquiry with the number of shares you hold in demat. Once the price is agreed, you transfer the shares from your demat account and the money is paid to a bank account in your name.
Is RoyalCare Super Speciality Hospital planning an IPO?
RoyalCare Super Speciality Hospital Limited is currently at the "Pre-IPO" stage. No IPO date has been announced. A listing depends on the company and on regulatory approval.
What are RoyalCare Super Speciality Hospital's revenue and profit?
In FY25, RoyalCare Super Speciality Hospital Limited reported revenue of ₹353 Cr and a profit of ₹15 Cr, with a net worth of ₹318 Cr. The Financials section has the full statements for every year we hold.
Is it legal to buy unlisted shares in India?
Yes. Shares of unlisted public companies can be bought and sold off-market and transferred between demat accounts. They carry more risk than listed shares: prices are not set on an exchange, it can take time to find a buyer, and a listing is never guaranteed.
Is there a lock-in on RoyalCare Super Speciality Hospital shares after the IPO?
SEBI rules lock in shares held before an IPO for a period after listing, currently six months from allotment for most investors in a mainboard IPO. Shares bought now in the unlisted market would usually be covered by this lock-in.
How are gains on RoyalCare Super Speciality Hospital unlisted shares taxed?
Gains on unlisted shares held for more than 24 months are long-term capital gains; held for less, they are short-term and taxed at your slab rate. Check the current rates with a tax adviser before you sell.

